Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and safety evaluation of SGLT2i on blood pressure control in patients with type 2 diabetes and hypertension: a new meta-analysis
Qin Zhang, Siyuan Zhou, Lijun Liu
Diabetology & Metabolic Syndrome (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Acute Coronary Syndrome: A Modern Cinderella?
Paschalis Karakasis, Nikolaos Fragakis, Κωνσταντίνος Κούσκουρας, et al.
Clinical Therapeutics (2024) Vol. 46, Iss. 11, pp. 841-850
Closed Access | Times Cited: 15
The relationship between SGLT2 and systemic blood pressure regulation
Priscilla Ahwin, Diana Martínez
Hypertension Research (2024) Vol. 47, Iss. 8, pp. 2094-2103
Open Access | Times Cited: 13
SGLT2 inhibitors decrease overhydration and proteasuria in patients with chronic kidney disease: a longitudinal observational study
Anja Schork, Marie-Luise Eberbach, Bernhard N. Bohnert, et al.
Kidney & Blood Pressure Research (2024)
Open Access | Times Cited: 6
Outpatient management of essential hypertension: a review based on the latest clinical guidelines
Areesha Moiz, Tetiana Zolotarova, Mark J. Eisenberg
Annals of Medicine (2024) Vol. 56, Iss. 1
Open Access | Times Cited: 6
Empagliflozin-based quadruple oral therapy for type 2 diabetes: a prospective cohort study
Fatemeh Moosaie, Shiva Abedinzadeh, Soghra Rabizadeh, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Sodium Glucose Cotransporter 2 Inhibitors Across the Spectrum of Cardiovascular Kidney Metabolic Syndrome
Kevin Bryan Lo, Karim Iskarous, Rajiv Sankaranarayanan
Cardiology Clinics (2025)
Closed Access
Immunological insights into hypertension: unraveling triggers and potential therapeutic avenues
Brandon Shokoples, Pierre Paradis, Ernesto L. Schiffrin
Hypertension Research (2024) Vol. 47, Iss. 8, pp. 2115-2125
Closed Access | Times Cited: 4
Sodium–Glucose Cotransporter Inhibitors: Cellular Mechanisms Involved in the Lipid Metabolism and the Treatment of Chronic Kidney Disease Associated with Metabolic Syndrome
Fernando Cortés-Camacho, Oscar René Zambrano-Vásquez, Elena Arechaga‐Ocampo, et al.
Antioxidants (2024) Vol. 13, Iss. 7, pp. 768-768
Open Access | Times Cited: 4
Perioperative and periprocedural management of GLP-1 receptor-based agonists and SGLT2 inhibitors: narrative review and the STOP-GAP and STOP DKA-2 algorithms
Ronald Goldenberg, Jeremy Gilbert, Robyn L. Houlden, et al.
Current Medical Research and Opinion (2025), pp. 1-17
Closed Access
The effect of empagliflozin and sitagliptin as an add-on therapy to metformin in blood pressure reduction in diabetic patients in primary health care settings in Riyadh, Saudi Arabia
Mayada Ahmed, Mohammed Altoyan, Raghad Hijazi, et al.
Journal of Family Medicine and Primary Care (2025) Vol. 14, Iss. 3, pp. 1116-1121
Open Access
Respiratory modulation of sympathetic transduction to blood pressure in health and type 2 diabetes
Michael Plunkett, Seth W. Holwerda, Benjamin E. Young, et al.
The Journal of Physiology (2024) Vol. 602, Iss. 16, pp. 3909-3927
Closed Access | Times Cited: 3
Advances in the Insulin–Heart Axis: Current Therapies and Future Directions
Alfredo Caturano, Erica Vetrano, Raffaele Galiero, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 18, pp. 10173-10173
Open Access | Times Cited: 2
Sodium-glucose cotransporter 2 inhibitors: mechanisms of cardiorenal protection: A review
М. В. Леонова
Consilium Medicum (2024) Vol. 26, Iss. 4, pp. 225-231
Open Access | Times Cited: 1
Arterial hypertension—clinical trials update 2024
Mert Tokcan, Lucas Lauder, Felix Götzinger, et al.
Hypertension Research (2024)
Closed Access | Times Cited: 1
SGLT2 Inhibitors for Cardioprotection
Sulthan Al Rashid, P Elango, Syed Ziaur Rahman
Oman Medical Journal (2023) Vol. 38, Iss. 4, pp. e521-e521
Open Access | Times Cited: 3
Neuroprotective effects of glucose-lowering drugs in rat focal brain ischemia-reperfusion model
А. В. Симаненкова, О. С. Фукс, Н. В. Тимкина, et al.
Arterial’naya Gipertenziya (Arterial Hypertension) (2023) Vol. 29, Iss. 6, pp. 579-592
Open Access | Times Cited: 3
Sodium-Glucose Cotransporter 2 Inhibitors' Mechanism of Action and Use in Kidney Transplantation Recipients: Extended Review and Update
Elmukhtar Habas, Ala Habas, Islam Elzouki, et al.
Journal of Diabetes and Endocrine Practice (2024) Vol. 07, Iss. 02, pp. 066-076
Open Access
A comprehensive meta-analysis on the association of SGLT2is and GLP-1RAs with vascular diseases, digestive diseases and fractures
Dehua Wang, Yu-Xia Mo, Xiang Tan, et al.
Acta Diabetologica (2024) Vol. 61, Iss. 9, pp. 1097-1105
Closed Access
Benefits of using SLGT2 Inhibitors for Patients with CDK and DM2 to Reduce Mortality Risks
Fonseca Pandora Eloa Oliveira, Azevedo Jeremias Aguiar, Bié Sara Maria Gomes, et al.
Archives of Pharmacy and Pharmaceutical Sciences (2024) Vol. 8, Iss. 1, pp. 041-046
Open Access
Antihypertensive effects of SGLT2 inhibitors; a letter to the editor on new concepts
Rahimeh Eskandarian, Mohammad Memarian, Samira Mehrabi Pari
Journal of Nephropharmacology (2024) Vol. 13, Iss. 2, pp. e12700-e12700
Open Access
SGLT-2 inhibitors in heart failure: a literature review on mechanisms, efficacy and safety
Klaudia Kułak, Katarzyna Chamera-Cyrek, Izabela Janik, et al.
Quality in Sport (2024) Vol. 15, pp. 52083-52083
Open Access
Mechanistic Insights into the Synergistic Effects of SGLT-2 Inhibitors and ACE Inhibitors/ARBs: Implications for Cardiovascular and Renal Protection in Type 2 Diabetes Mellitus and Beyond
Sulthan Al Rashid, Mohammad Fareed
Journal of Diabetology (2024) Vol. 15, Iss. 3, pp. 319-320
Open Access
SGLT2i and GLP1RA effects in patients followed in a hospital diabetology consultation
António Cabral Lopes, Olga Lourenço, Manuel Morgado
Expert Review of Clinical Pharmacology (2024) Vol. 17, Iss. 11, pp. 1081-1088
Closed Access
Cardio-renal protective effect and safety of sodium-glucose cotransporter 2 inhibitors for chronic kidney disease patients with eGFR < 60 mL/min/1.73 m2: a systematic review and meta-analysis
Yaru Zhang, Junhui Luo, Bingxin Li, et al.
BMC Nephrology (2024) Vol. 25, Iss. 1
Open Access
Sodium Chloride Cotransporter in Hypertension
Annalisa Castagna, Gabriele Mango, Nicola Martinelli, et al.
Biomedicines (2024) Vol. 12, Iss. 11, pp. 2580-2580
Open Access
Page 1 - Next Page

Scroll to top